Cohort 1: niraparib monotherapy
serous, thrombocytopenia, anaemia, fatigue
ADVERSE EVENTS, ADVERSE EVENT, THROMBOCYTOPENIA, ANAEMIA
Twenty-five patients were enrolled (Fig Median number of cycles of niraparib was three (1–8). The clinical benefit rate (CBR) was 20% (5/25; 95% CI: 9–39), with a median clinical benefit duration of 5.3 months (range 1.8–7.2). The ORR was 4% (1/25; 95% confidence interval [CI] 0–20), with one patient with serous EC experiencing a partial response (Fig. Adverse events that were considered to be related to therapy were mostly grade 1–2. Related grade ≥3 adverse events (AEs) occurring in ≥ 10% of patients were anaemia (24%), fatigue (16%) and thrombocytopenia (16%). Any AE occurring in ≥15% of patients is shown on Table Adverse events occurring in ≥15% of patients in any treatment groupData are represented in 